Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2021 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
TRDA on Nasdaq
Shares outstanding
38,346,880
Price per share
$11.30
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
24,407,232
Total reported value
$250,738,606
% of total 13F portfolios
0%
Share change
+473,317
Value change
+$6,140,638
Number of holders
111
Price from insider filings
$11.30
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
5AM Ventures V, L.P. 11% $25,485,387 4,123,849 Kush Parmar 14 Nov 2025
ROCHE FINANCE LTD 6.9% $23,019,270 2,569,115 Roche Finance Ltd 31 Dec 2024
BlackRock, Inc. 5.3% $17,691,090 1,974,452 BlackRock, Inc. 31 Dec 2024
TCG Crossover GP I, LLC 5% $11,849,186 1,917,344 TCG Crossover GP I, LLC 19 Nov 2025
JANUS HENDERSON GROUP PLC 4% -27% $9,964,391 -$3,932,443 1,521,281 -28% JANUS HENDERSON GROUP PLC 30 Jun 2025
PRICE T ROWE ASSOCIATES INC /MD/ 0.9% -84% $2,091,051 -$12,800,322 360,526 -86% T. Rowe Price Associates, Inc. 30 Sep 2025

As of 31 Dec 2025, 111 institutional investors reported holding 24,407,232 shares of Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA). This represents 64% of the company’s total 38,346,880 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA) together control 58% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BAKER BROS. ADVISORS LP 13% 5,072,730 +4.3% 0.31% $52,147,664
5AM Venture Management, LLC 11% 4,056,379 -4.7% 13% $41,699,576
BlackRock, Inc. 5.6% 2,147,260 +5% 0% $22,073,833
TCG Crossover Management, LLC 5.4% 2,088,392 +257% 0.71% $21,468,670
VANGUARD GROUP INC 4.3% 1,632,460 +1.8% 0% $16,781,689
WELLINGTON MANAGEMENT GROUP LLP 2.7% 1,044,758 +9.5% 0% $10,740,113
StepStone Group LP 2% 761,277 0% 4.5% $7,825,928
GEODE CAPITAL MANAGEMENT, LLC 1.7% 639,947 -0.8% 0% $6,580,002
STATE STREET CORP 1.3% 508,789 +2% 0% $5,230,351
MILLENNIUM MANAGEMENT LLC 1.3% 497,695 -41% 0% $5,116,305
JACOBS LEVY EQUITY MANAGEMENT, INC 0.95% 362,786 +15% 0.01% $3,729,440
PRICE T ROWE ASSOCIATES INC /MD/ 0.85% 327,423 -9.2% 0% $3,367,000
ACADIAN ASSET MANAGEMENT LLC 0.81% 310,833 +4.3% 0.01% $3,193,000
CITADEL ADVISORS LLC 0.76% 292,770 -13% 0% $3,009,676
DIMENSIONAL FUND ADVISORS LP 0.71% 273,378 -31% 0% $2,809,666
MORGAN STANLEY 0.68% 260,251 -25% 0% $2,675,384
RENAISSANCE TECHNOLOGIES LLC 0.66% 252,635 -57% 0% $2,597,088
ROYCE & ASSOCIATES LP 0.64% 247,147 -28% 0.03% $2,540,671
NORTHERN TRUST CORP 0.59% 226,301 -11% 0% $2,326,375
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.58% 221,269 +19% 0% $2,274,645
GOLDMAN SACHS GROUP INC 0.54% 205,173 -7.7% 0% $2,109,181
BNP PARIBAS FINANCIAL MARKETS 0.47% 180,969 0% 0% $1,860,361
Qube Research & Technologies Ltd 0.46% 176,018 -39% 0% $1,809,465
Woodline Partners LP 0.37% 142,110 0.01% $1,460,891
ALGERT GLOBAL LLC 0.34% 128,611 -0.93% 0.02% $1,322,000

Institutional Holders of Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 24,407,232 $250,738,606 +$6,140,638 $10.28 111
2025 Q3 28,408,651 $164,766,270 -$9,410,304 $5.80 114
2025 Q2 29,583,750 $198,790,015 -$4,881,409 $6.72 105
2025 Q1 30,241,830 $274,509,238 -$4,478,805 $9.04 110
2024 Q4 30,637,008 $529,755,566 +$9,629,460 $17.29 102
2024 Q3 30,099,996 $481,057,545 +$6,089,620 $15.98 97
2024 Q2 29,668,185 $422,803,373 +$52,052,901 $14.25 82
2024 Q1 26,027,444 $368,797,900 -$3,772,264 $14.17 76
2023 Q4 26,281,861 $396,641,035 +$3,492,844 $15.09 62
2023 Q3 26,035,608 $411,375,608 +$4,515,692 $15.80 55
2023 Q2 25,751,810 $389,877,766 +$13,317,282 $15.14 56
2023 Q1 24,900,040 $361,043,649 +$2,708,627 $14.50 53
2022 Q4 24,715,588 $334,178,958 +$2,434,963 $13.52 46
2022 Q3 24,517,008 $386,369,092 -$2,728,204 $15.76 33
2022 Q2 24,778,477 $301,833,417 -$12,927,920 $12.18 35
2022 Q1 25,876,494 $242,821,140 +$2,263,033 $9.39 48
2021 Q4 24,861,440 $425,110,000 +$413,748,000 $17.12 45